On November 24, 2021 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following investor conferences (Press release, Akebia, NOV 24, 2021, View Source [SID1234596042]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 33rd Annual Virtual Healthcare Conference
November 29 – December 2, 2021
John Butler will participate in a virtual fireside chat, which will be available on the conference site prior to the virtual event.

4th Annual Evercore ISI HealthCONx Conference
November 30 – December 2, 2021
John Butler will participate in a virtual fireside chat, which will be presented on Tuesday, November 30 at 4:45 on the conference site.

Where applicable, webcasts of Akebia’s fireside chats will be made available on the Investors section of the Company’s website at View Source

On November 24, 2021 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, reported that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Nov 30, 2021, at 8:00 AM EST (Press release, Molecular Partners, NOV 24, 2021, View Source [SID1234596041]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcasted presentation will be made available on the Molecular Partners website.

On November 24, 2021 Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, reported that it will be presenting at the SNN Network Canada Virtual Event 2021 on Wednesday, December 8, 2021 at 11:00 a.m. ET (Press release, Nuvo Pharmaceuticals, NOV 24, 2021, View Source [SID1234596032]). Jesse Ledger, President & Chief Executive Officer and Mary-Jane Burkett, Vice President & Chief Financial Officer of Miravo will be hosting the presentation and answering questions from investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live presentation, please use the following information:

SNN Network Canada Virtual Event 2021

Date: Wednesday, December 8, 2021
Time: 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time)
Webcast: View Source

If you would like to book 1on1 investor meetings with Miravo Healthcare, and to watch Miravo Healthcare’s presentation, please make sure you are registered for the virtual event here: View Source

1on1 meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

The SNN Network Canada Virtual Event website is available here: View Source

If you can’t make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": View Source

On November 24, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, reported that the company will participate in the 4th Annual Evercore ISI HealthCONx Conference (Press release, Revolution Medicines, NOV 24, 2021, View Source [SID1234596030]). Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

4th Annual Evercore ISI HealthCONx Conference
Conference Date: November 30 – December 2, 2021
Fireside Chat Time/Date: 11:45 a.m. Eastern on Thursday, December 2, 2021
Format: Virtual conference; webcast available
To access the live webcast of the fireside chat, please visit the "Events & Presentations" page of Revolution Medicines’ website at View Source Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

On November 24, 2021 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that Frank Clyburn, executive vice president and president of Human Health, is scheduled to participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021 at 10:30 a.m. ET (Press release, Merck & Co, NOV 24, 2021, View Source [SID1234596029]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to watch a live video webcast of the presentations at View Source